BIOGEN INC. Operating Lease Cost
BIOGEN INC. (BIIB) reported Operating Lease Cost of $15.90 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-10-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2019-10-22
- BIOGEN INC. operating lease, cost for the quarter ending 2019-09-30 was $15.90M.
- BIOGEN INC. operating lease, cost for the quarter ending 2019-06-30 was $14.40M.
- BIOGEN INC. operating lease, cost for the quarter ending 2019-03-31 was $15.70M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month |
|---|---|---|---|
| 2019-09-30 | $15.90M 10-Q · filed 2019-10-22 | $30.30M derived: sum of 2 quarters · filed 2019-10-22 | $46.00M 10-Q · filed 2019-10-22 |
| 2019-06-30 | $14.40M 10-Q · filed 2019-07-24 | $30.10M 10-Q · filed 2019-07-24 | |
| 2019-03-31 | $15.70M 10-Q · filed 2019-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |